Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
➜ Over Stichting PSMA forum
➜ Word donateur
➜ Sponsoren
➜ Vergaderingen
➜ Links
➜ Richtlijnen en protocollen
➜ Landelijke samenwerking
➜ Publicaties
➜ (Pers)berichten
➜ Filmpjes
➜ Contact
Toegankelijkheid gereedschappen